2:28 PM
 | 
Aug 01, 2018
 |  BioCentury  |  Finance

Safety goes (Re)Viral

Strong safety data prompted Novo to co-lead ReViral’s $55M series B

The clean safety profile and clinical efficacy of ReViral Ltd.’s respiratory syncytial virus therapy prompted Novo Ventures to co-lead the biotech’s $55 million series B round with fellow new investor New Leaf Venture Partners.

The round closed Wednesday and saw participation from new investor Perceptive Advisors and existing investors Andera Partners, OrbiMed and Brace Pharma Capital.

ReViral CEO Eddy Littler said the majority of the round will go towards two Phase II trials of lead compound RV521 to treat RSV...

Read the full 380 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >